Anti-tumor composition and application thereof
Through the combination of mitochondrial autophagy agonists and chemotherapy drugs, the mitochondrial autophagy process is regulated, which significantly improves the therapeutic effect of tumors such as liver cancer, and solves the problem of low sensitivity of existing chemotherapy methods to liver cancer, achieving more effective tumor suppression .
Patent Information
- Application Number
- CN202411193408.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-28
AI Technical Summary
The existing tumor chemotherapy methods are not very sensitive to malignant tumors such as liver cancer, and lack effective chemotherapy sensitizers, resulting in poor treatment effect.
Mitochondrial autophagy agonists (such as CCCP, olapanib or ketoconazole) combined with chemotherapy drugs (such as epirubicin, cisplatin or pentafluorouracil) are used to enhance inhibition of tumor cells by regulating the mitochondrial autophagy process. effect.
This composition significantly improves the therapeutic effect of tumors such as liver cancer, and produces synergistic effects through combination of drugs, which significantly enhances the inhibition and apoptosis effects on tumor cells, and solves the problem of low chemotherapy sensitivity.
Smart Images

Figure HDA0005015696900000011 
Figure HDA0005015696900000012 
Figure HDA0005015696900000021
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to an anti-tumor composition and application thereof. Background Art
[0002] Tumors are new organisms formed by abnormal proliferation and differentiation of body cells, including benign tumors and malignant tumors (cancer). Benign tumors usually grow slowly, have clear boundaries, do not invade surrounding tissues, and have no metastatic ability, while malignant tumors grow rapidly, can invade surrounding tissues and organs, and metastasize to distant sites. Malignant tumors are one of the major diseases that threaten human health, and their occurrence is related to multiple factors such as genetics, environment, and lifestyle.
[0003] Treatment options for tumors mainly include: surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy. With the continuous advancement of medical technology, new treatment methods and means continue to emerge, bringing more hope and options to tumor patients.
[0004] Mitophagy is one of the pathways of intracellular autophagy. It selectively self-degrades damaged mitochondria, which helps cells to remove aging and diseased mitochondria under normal physiological conditions. It is a conservative biological self-defense mechanism to maintain the homeostasis of the intracellular environment. When mitochondria are damaged or diseased due to various factors, the permeability and potential of the mitochondrial membrane change, and PTEN-induced putative kinase-1 (PINK1) and Parkin E3 ubiquitin ligase are induced and activate downstream biochemical responses. Under normal physiological conditions, PINK1 can be rapidly degraded after targeting mitochondria. However, when mitochondria are damaged or undergo other pathological changes, PINK1 cannot enter mitochondria due to changes in mitochondrial membrane permeability and potential. Instead, it is riveted to the outer membrane of mitochondria. Through its phosphorylase activity, it phosphorylates and activates ubiquitin and Parkin's ubiquitin-like domains and enriches them around mitochondria. It further recruits autophagy-related receptors such as NDP52 and optineurin (OPTN), which activate microtubule-associated protein 1 light chain 3 (LC3), especially LC3B-I, which is converted into lipidated LC3B-II. At the same time, autophagy-related receptors also promote the formation of a large number of mitochondrial autophagosomes, which are the main sites for contact and fusion between mitochondria and organelles such as the endoplasmic reticulum and lysosomes, affecting the final outcome of mitochondrial autophagosomes.
[0005] Appropriate levels of mitochondrial autophagy are one of the survival strategies of tumors. In extreme cases of tumor death caused by resistance to chemotherapeutic drug killing, anti-tumor immunity, cell apoptosis caused by high oxygen free radical (ROS) levels, nutrient deficiency, hypoxia, etc., appropriate mitochondrial autophagy is a self-protection mechanism for tumor cells to use limited energy to remove harmful or damaged mitochondria, thereby reducing apoptotic cell death caused by excessive mitochondrial damage. However, excessive mitochondrial autophagy is a process of exhausting mitochondria, which is not conducive to the survival of tumor cells. At the same time, the mitochondrial autophagy signaling pathway of tumor cells is abnormal and is also closely related to events such as mitochondrial-induced apoptosis. When the metabolic pressure caused by the killing effect of drugs on cells, DNA damage, inflammation, hypoxia and nutrient deficiency exceeds a certain threshold or triggers abnormal mitochondrial autophagy switches, mitochondrial autophagy can be aggravated, causing cell death. For example, under the action of chemotherapeutic drugs, targeted molecular drugs, etc., the irreversible process of mitochondrial autophagy can be caused, ultimately causing cell death. Therefore, proper mitochondrial autophagy is an important pathway for tumor cell survival and drug resistance, while excessive mitochondrial autophagy causes excessive mitochondrial damage, which can lead to cell apoptosis or even death.
[0006] Targeting the mitochondrial autophagy process is an emerging direction for the development of chemotherapy sensitization drugs, but it is still limited to basic research. Therefore, finding drugs with mitochondrial autophagy regulation in clinical drugs as a combination drug regimen for chemotherapy sensitization is expected to quickly transform basic research ideas into clinical applications. Summary of the invention
[0007] In view of this, the technical problem to be solved by the present invention is to provide an anti-tumor composition and application thereof.
[0008] The composition provided by the present invention is composed of a mitochondrial autophagy agonist and a chemotherapeutic drug.
[0009] The chemotherapy drug is selected from at least one of epirubicin, platinum chemotherapy drugs or pentafluorouracil;
[0010] The mitochondrial autophagy agonist is selected from at least one of CCCP, olaparib or ketoconazole.
[0011] The platinum-based chemotherapy drugs include cisplatin and other platinum-based chemotherapy drugs; and their salts or derivatives of the same name. For example, cisplatin, carboplatin or oxaliplatin. The present invention has found that the combined use of mitochondrial autophagy agonists and chemotherapy drugs (epirubicin, cisplatin and 5-fluorouracil) has an inhibitory effect on liver cancer ( Figure 1), and proved that the combination of the two drugs can produce significant synergistic effects. In the present invention, the two drugs in the composition can be mixed or exist independently of each other, and the present invention does not limit this.
[0012] In the present invention, the mass ratio of the mitophagy agonist to the chemotherapeutic drug is 1:(0.0005-1000). Preferably, the mass ratio of the mitophagy agonist to the chemotherapeutic drug is 1:(0.0025-500). For example, the mass ratio of the mitophagy agonist to the chemotherapeutic drug is (0.62-26):(0.1-1.6).
[0013] In some embodiments, the composition is composed of epirubicin and CCCP, wherein the mass ratio of epirubicin to CCCP is (0.1-1.6):(0.62-10) or (0.4-1.6):(0.62-10) or (0.8-1.6):(0.62-10) or 1.6:(0.62-10) or 1.6:(2.5-10) or 1.6:(5-10); in some specific embodiments, the mass ratio of epirubicin to CCCP is 0.1:0.62, 0.1:1 .25, 0.1:2.5, 0.1:5, 0.1:10, 0.2:0.62, 0.2:1.25, 0.2:2.5, 0.2:5, 0.2:10, 0.4:0.62, 0.4:1.25, 0.4:2.5, 0.4:5, 0.4:10, 0.8:0.62, 0.8:1.25, 0.8:2.5, 0.8:5, 0.8:10, 1.6:0.62, 1.6:1.25, 1.6:2.5, 1.6:5, or 1.6:10.
[0014] In other embodiments, the composition is composed of epirubicin and olaparib, wherein the mass ratio of epirubicin to olaparib is (0.1-1.6):(1.25-20) or (0.1-1.6):(5-20) or 1.6:(1.25-2.5) or (0.4-1.6):(5-20) or (0.1-1.6):20 or 0.4:(5-20) or 0.4:(5-10); in some specific embodiments, the mass ratio of epirubicin to olaparib is 0.1:1 .25, 0.1:2.5, 0.1:5, 0.1:10, 0.1:20, 0.2:1.25, 0.2:2.5, 0.2:5, 0.2:10, 0.2:20, 0.4:1.25, 0.4:2.5, 0.4:5, 0.4:10, 0.4:20, 0.8:1.25, 0.8:2.5, 0.8:5, 0.8:10, 0.8:20, 1.6:1.25, 1.6:2.5, 1.6:5, 1.6:10, or 1.6:20.
[0015] In other embodiments, the composition is composed of epirubicin and ketoconazole, wherein the mass ratio of epirubicin to ketoconazole is (0.1-1.6):(1.62-26) or (0.4-1.6):(1.62-26) or (0.4-1.6):(6.5-26) or (0.8-1.6):(6.5-26) or 1.6:(6.5-26) or 1.6:(13-26). In some specific embodiments, the mass ratio of epirubicin to ketoconazole is 0.1:1.62, 0.1:3.25, 0.1:6.5, 0.1:13, 0.1:26, 0.2:1.62, 0.2:3.25, 0.2:6.5, 0.2:13, 0.2:26, 0.4:1.62, 0.4:3.25, 0.4:6.5, 0.4:13, 0.4:26, 0.8:1.62, 0.8:3.25, 0.8:6.5, 0.8:13, 0.8:26, 1.6:1.62, 1.6:3.25, 1.6:6.5, 1.6:13 or 1.6:26.
[0016] The present invention also provides use of the composition as described in any of the preceding items in the preparation of anti-tumor drugs.
[0017] In some embodiments, the tumor is liver cancer, gallbladder cancer, pancreatic cancer, small intestine tumor, colon cancer / colorectal cancer, esophageal cancer, gastric cancer, digestive system tumor, bladder cancer, blood system tumor, bone tumor, cartilage tumor, lung cancer, tracheal tumor, glottis cancer, brain cancer, central nervous system tumor, peripheral nervous system tumor, head and neck tumor, kidney cancer, laryngeal cancer, nasopharyngeal cancer, lung cancer, muscle tissue cancer, oral or nasal mucosal cancer, ovarian cancer, breast cancer, prostate cancer, cervical cancer, endometrial cancer, external genital tumor, urogenital tract tumor, adrenal tumor, skin cancer, spleen tumor, testicular cancer and / or thyroid cancer. In a specific embodiment, the tumor is liver cancer. More specifically, the tumor is primary liver cancer. More specifically, the tumor is hepatocellular carcinoma.
[0018] In some embodiments, the anti-tumor effect includes inhibiting tumor cell activity and / or promoting tumor cell apoptosis.
[0021] In some specific embodiments, in the anti-tumor agent, the tumor cells are liver cancer cells, and more specifically, the liver cancer cells are MHCC97H and / or Bel-7402.
[0022] Furthermore, the present invention also provides an anti-tumor drug, which comprises the above-mentioned composition and a pharmaceutically acceptable excipient.
[0023] The pharmaceutically acceptable excipients include one or a mixture of two or more of flavoring agents, fillers, lubricants, preservatives, suspending agents, food coloring agents, diluents, emulsifiers, disintegrants or plasticizers.
[0024] The dosage form of the drug of the present invention is a dosage form for gastrointestinal administration and / or a dosage form for parenteral administration.
[0025] The dosage form for administration through the gastrointestinal tract is powder, tablet, granule, capsule, solution, emulsion or suspension.
[0026] The non-intestinal administration dosage form is an injection dosage form, a respiratory tract administration dosage form, a skin administration dosage form, a mucosal administration dosage form or a cavity administration dosage form.
[0027] The present invention does not limit the content of the composition in the medicine, nor does it limit the dosage per administration. Preferably, the dosage administered is not less than the effective dosage. In the medicine, the dosage of the composition is also not less than the effective amount.
[0028] The drug of the present invention also includes other therapeutic agents with anti-tumor activity, which are selected from mitomycin, gemcitabine, capecitabine, irinotecan, oxaliplatin, cyclophosphamide, methotrexate, adriamycin, vincristine, sorafenib, sunitinib, bevacizumab, erlotinib, lenvatinib mesylate capsules, regorafenib, lenvatinib, entecavir, extended polyethylene glycol (PEG) Alfa-2a), interferon, lamivudine, icariin, huachansu capsule, Kanglaite injection, Cidan capsule, sodium cantharidate vitamin B6 injection, Jinlong capsule, Biejiajian pill, Huaier granules, elemene injection, Kangai injection, Aidi injection, Ganfule capsule, Brucea javanica oil soft capsule, compound cantharidin capsule, transfer factor, various immune checkpoint drugs (PD-1 antibody, PD-L1 antibody, TIGIT antibody, CTLA4 antibody, etc.), gamma globulin; various Chinese medicine mixtures, including but not limited to Chaihu Shugan San plus or minus in Jingyue Quanshu, Gexia Zhuyu Tang plus or minus in Yilin Gaicuo, Xiaoyao San plus or minus in Taiping Huimin Heji Jufang, Yinchenhao Tang plus or minus Wuling San in Shanghan Lun, and Yiguanjian plus or minus in Liuzhou Yihua.
[0029] The present invention also provides an anti-tumor method, which comprises administering the above-mentioned drug or the above-mentioned composition.
[0030] In the anti-tumor method of the present invention, two or more active ingredients are administered simultaneously or successively, and the present invention does not limit this. The dosing interval of the pre- and post-administration is any time interval within 30 days, preferably any time interval within 3 days, preferably not longer than 24 hours, preferably not longer than 12 hours, preferably not longer than 6 hours, preferably not longer than 5 hours, more preferably not longer than 4 hours, even more preferably not longer than 3 hours, more preferably not longer than 2 hours and most preferably not longer than 1 hour and / or not longer than 6 hours, preferably not longer than 5 hours, more preferably not longer than 4 hours, even more preferably not longer than 3 hours, more preferably not longer than 2 hours and most preferably not longer than 1 hour after the administration of other therapeutic agents.
[0031] In the anti-tumor method described in the present invention, the administration method of the drug includes but is not limited to sublingual administration, oral administration, subcutaneous injection, intradermal injection, intramuscular injection, intravenous injection, intravenous drip, intraperitoneal administration, anal administration, airway administration, transdermal or other mucosal administration, etc.
[0032] In the anti-tumor method described in the present invention, the administration frequency of two or more drugs can be the same or different, and the present invention is not limited to this. For example, the administration frequency of two or more drugs in the drug is independently selected from 1 month / time, 15 days / time, 7 days / time, once every other day, 1 time / day, 2 times / day, 3 times / day or 4 times / day.
[0033] The present invention provides a combination of a mitochondrial autophagy agonist and a chemotherapy drug that can produce a more effective inhibitory effect on tumors, and experiments have shown that the combination of the two drugs can produce a significant synergistic effect. In particular, the combination of the two drugs has a good therapeutic effect on liver cancer, solving the clinical problem that liver cancer has low chemotherapy sensitivity and there is currently no clinically available chemotherapy sensitizer. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 Schematic diagram: Mitochondrial autophagy agonists (CCCP, Olaparib, Ketoconazole) combined with chemotherapy drugs (epirubicin, cisplatin, and 5-Fu) for the treatment of liver cancer;
[0035] Figure 2 Scanning electron microscopy (TEM) verifies that three mitophagy activators induce mitophagy in liver cancer cells: (A) TEM confirms that three mitophagy activators (CCCP, ketoconazole and olaparib) induce mitophagy in HCC cancer cell line (Bel-7402); (B) TEM shows statistical analysis of mitophagosomes in liver cancer cells (Bel-7402) (n=50 in each group, 10 in each group); (C) TEM confirms that three mitophagy activators (CCCP, ketoconazole and olaparib) induce mitophagy in HCC cancer cell line (MHCC97H); (D) TEM shows statistical analysis of mitophagosomes in liver cancer cells (MHCC97H) (n=50 in each group, 10 in each group);
[0036] Figure 3To investigate the effect of mitochondrial autophagy activators on enhancing the effect of the chemotherapy drug epirubicin in liver cancer, the Syngerfinder platform was used for analysis. (A) was the drug synergy analysis of epirubicin and CCCP, and the dose-response matrix and 2D and 3D drug synergy models were obtained (ZIP synergy score 7.109±2.73); (B) was the drug synergy analysis of epirubicin and olaparib, and the dose-response matrix and 2D and 3D drug synergy models were obtained (ZIP synergy score 5.884±3.32); (C) was the drug synergy analysis of epirubicin and ketoconazole, and the dose-response matrix and 2D and 3D drug synergy models were obtained (ZIP synergy score 3.423±1.24).
[0037] Figure 4 Through the analysis of the Syngerfinder platform, the Bliss synergy score of epirubicin and CCCP was 6.995±2.73; the Bliss synergy score of epirubicin and olaparib was 5.884±3.32; and the Bliss synergy score of epirubicin and ketoconazole was 3.342±1.24.
[0038] Figure 5 Through the analysis of the DrugComb platform, the LOEWE synergy scores of epirubicin and CCCP were (9.61, 18.68, 8.84); the LOEWE synergy scores of epirubicin and olaparib were (5.60, 9.25, 8.85); and the LOEWE synergy scores of epirubicin and ketoconazole were (6.72, 7.68, 6.13).
[0039] Figure 6 Through the analysis of DrugComb platform, the HSA synergy scores of epirubicin and CCCP were (13.39, 12.74, 11.65); the HSA synergy scores of epirubicin and olaparib were (11.97, 9.35, 14.17); and the HSA synergy scores of epirubicin and ketoconazole were (9.60, 10.90, 9.95). DETAILED DESCRIPTION
[0040] The present invention provides an antitumor composition and its application. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0041] Unless otherwise defined herein, scientific and technical terms related to the present invention shall have the meanings understood by those of ordinary skill in the art.
[0042] Furthermore, unless otherwise indicated herein, singular terms shall include pluralities and plural terms shall include the singular. More specifically, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless expressly indicated otherwise.
[0043] The terms "include", "comprising" and "having" are used interchangeably herein and are intended to indicate the inclusiveness of the solution, meaning that the solution may have other elements in addition to the listed elements. At the same time, it should be understood that the use of "include", "comprising" and "having" descriptions herein also provides a "consisting of..." solution.
[0044] The term "and / or" as used herein includes the meanings of "and", "or" and "all or any other combination of elements linked by the term". In this application, the term "and / or" describes the association relationship of associated objects, indicating that three relationships may exist. For example, A and / or B may represent: A exists alone, A and B exist at the same time, and B exists alone. A and B may be singular or plural.
[0045] In this application, "at least one" means one or more, "more than one" means two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single or plural items.
[0046] In this application, the numerical ranges and parameters involved have been presented in the specific embodiments as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise explicitly stated, it should be understood that all numerical ranges or specific data used in this disclosure may have certain reasonable deviations within a certain range, for example: within ±10%, ±5%, ±1% or ±0.5%.
[0047] In the embodiment of the present invention, propofol combined with epirubicin is used as an example to find that propofol combined with chemotherapy drugs can effectively inhibit liver cancer. In fact, propofol combined with various chemotherapy drugs can achieve the effect of treating liver cancer, not limited to propofol combined with epirubicin, propofol combined with cisplatin, propofol combined with 5-Fu and other combined medication schemes, and the medication method is not limited to simultaneous administration, asynchronous administration, sequential administration, administration of various mixtures, etc.
[0048] In the present application, the subject of the liver cancer inhibition is a human or a mammal, and the mammal includes bovines, equines, ovines, porcines, canines, felines, rodents, and primates.
[0049] The test materials used in the present invention are all common commercial products and can be purchased in the market.
[0050] Among them, CCCP / Carbonyl Cyanide m-Chlorophenylhydrazone, or: Carbonylcyanide 3-chlorophenylhydrazone; Carbonyl Cyanide m-Chlorophenylhydrazone
[0051] Olaparib, whose English name is Olaparib.
[0052] Ketoconazole, English name Ketoconazole.
[0053] Epirubicin is also known as epirubicin and its English name is Epidoxorubicin.
[0054] Cisplatin also includes other platinum-derived chemotherapy drugs; and their salts or derivatives with the same name.
[0055] Pentafluorouracil / 5-Fu is also known as 5-fluorouridine nucleoside, and its English name is 5-Fluorouracil. The non-fluorouracil also includes its salts or derivatives with the same name.
[0056] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.
[0057] Some cases are recorded in the embodiments of the present invention. The embodiments show some implementation methods of the present invention. However, this does not mean that the effects of the present invention can only be achieved in these cases. In fact, any concentration of each component between the two endpoint values shown in the embodiments can achieve a good anti-tumor effect. In addition, many attempts have been made during the research and development process, such as using different chemotherapy drugs or propofol analogs, using different ratios, etc. to perform tumor cell inhibition experiments, but the effects of these attempts are not as good as those recorded in the embodiments, and will not be repeated here.
[0058] The present invention will be further described below in conjunction with embodiments:
[0059] Example
[0060] In the preliminary experiment, a preliminary safety experiment (IC50) was carried out on the drug concentrations shown in the following examples, and the combination regimen for treating in vivo and in vitro liver cancer models was determined through combined drug experiments and IC50 concentration detection again. The selected combined drug concentration was lower than the IC50 of the above-mentioned single drug, and in the regimen described in this case, the drug dose was much lower than the median lethal concentration (IC50, 0.1ug / ml or 0.17uM) for non-tumor cells HEK293T cells recorded in the existing literature (see J Nat Prod. 2016Sep23; 79(9): 2397-402.doi: 10.1021 / acs.jnatprod.6b00639.) or the highest clinical dose.
[0061] The above-mentioned mitochondrial autophagy agonist and epirubicin were used in a combination drug test on a liver cancer cell line (HepG2). We used the online combination drug analysis platform Syngerfinder (https: / / synergyfinder.fimm.fi) and DrugComb (https: / / drugcomb.fimm.fi) to analyze the synergistic effect of the drug combination.
[0062] Dosage:
[0063] Epirubicin: 0.1μg / ml, 0.2μg / ml, 0.4μg / ml, 0.8μg / ml, 1.6μg / ml;
[0064] CCCP: 0.62μg / ml, 1.25μg / ml, 2.5μg / ml, 5μg / ml, 10μg / ml;
[0065] Ketoconazole: 1.62μg / ml, 3.25μg / ml, 6.5μg / ml, 13μg / ml, 26μg / ml;
[0066] Olaparib: 1.25μg / ml, 2.5μg / ml, 5μg / ml, 10μg / ml, 20μg / ml.
[0067] The results are as follows Figures 2 to 6 As shown:
[0068] 1. Three mitophagy activators (CCCP, ketoconazole and olaparib) can induce mitophagy in liver cancer cells;
[0069] 2. The ZIP synergy score of epirubicin and CCCP was 7.109±2.73 according to the Syngerfinder platform; the ZIP synergy score of epirubicin and olaparib was 5.912±3.32; the ZIP synergy score of epirubicin and ketoconazole was 3.423±1.24. This indicates that epirubicin can produce synergistic effects with the three mitochondrial autophagy activators ( Figure 3 ).
[0070] 3. The Bliss synergy score of epirubicin and CCCP was 6.995±2.73 according to the Syngerfinder platform; the Bliss synergy score of epirubicin and olaparib was 5.884±3.32; the Bliss synergy score of epirubicin and ketoconazole was 3.342±1.24. This indicates that epirubicin can produce a synergistic effect with the three mitochondrial autophagy activators ( Figure 4 ).
[0071] 4. The LOEWE synergy scores of epirubicin and CCCP were (9.61, 18.68, 8.84) through the DrugComb platform analysis; the LOEWE synergy scores of epirubicin and olaparib were (5.60, 9.25, 8.85); and the LOEWE synergy scores of epirubicin and ketoconazole were (6.72, 7.68, 6.13). This indicates that epirubicin can produce a synergistic effect with the three mitochondrial autophagy activators ( Figure 5 ).
[0072] 5. According to the analysis of DrugComb platform, the HSA synergy scores of epirubicin and CCCP were (13.39, 12.74, 11.65); the HSA synergy scores of epirubicin and olaparib were (11.97, 9.35, 14.17); the HSA synergy scores of epirubicin and ketoconazole were (9.60, 10.90, 9.95). This indicates that epirubicin can produce synergistic effects with the three mitochondrial autophagy activators ( Figure 6 ).
[0073] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A composition consisting of a mitochondrial autophagy agonist and a chemotherapeutic drug, The chemotherapy drug is selected from at least one of epirubicin, cisplatin or pentafluorouracil; The mitochondrial autophagy agonist is selected from at least one of CCCP, olaparib or ketoconazole.
2. The composition according to claim 1, characterized in that The mass ratio of the mitochondrial autophagy agonist to the chemotherapy drug is 1:(0.0005-1000).
3. The composition according to claim 2, characterized in that The mass ratio of the chemotherapy drug to the mitochondrial autophagy agonist is (0.1-1.6):(0.62-26).
4. The composition according to claim 1, characterized in that The composition consists of epirubicin and CCCP, wherein the mass ratio of epirubicin to CCCP is (0.1-1.6):(0.62-10); Or the composition consists of epirubicin and olaparib, wherein the mass ratio of epirubicin to olaparib is (0.1-1.6):(1.25-20); Or the composition consists of epirubicin and ketoconazole, wherein the mass ratio of epirubicin to ketoconazole is (0.1-1.6):(1.62-26).
5. Use of the composition according to any one of claims 1 to 4 in the preparation of anti-tumor drugs.
6. The use according to claim 4, characterized in that: The tumor is liver cancer, gallbladder cancer, pancreatic cancer, small intestine tumor, large intestine cancer / colorectal cancer, esophageal cancer, gastric cancer, digestive system tumor, bladder cancer, blood system tumor, bone tumor, cartilage tumor, lung cancer, tracheal tumor, glottic cancer, brain cancer, central nervous system tumor, peripheral nervous system tumor, head and neck tumor, kidney cancer, laryngeal cancer, nasopharyngeal cancer, lung cancer, muscle tissue cancer, oral or nasal mucosal cancer, ovarian cancer, breast cancer, prostate cancer, cervical cancer, endometrial cancer, external genitalia tumor, urogenital tract tumor, adrenal tumor, skin cancer, spleen tumor, testicular cancer and / or thyroid cancer.
7. The use according to claim 4 or 5, characterized in that: The anti-tumor effect includes inhibiting tumor cell activity and / or promoting tumor cell apoptosis.
8. An anti-tumor drug comprising the composition according to any one of claims 1 to 4 and a pharmaceutically acceptable excipient.
9. The drug according to claim 8, characterized in that Other therapeutic agents with anti-tumor activity are also included, and the therapeutic agents are selected from mitomycin, gemcitabine, capecitabine, irinotecan, oxaliplatin, cyclophosphamide, methotrexate, doxorubicin, vincristine, sorafenib, sunitinib, bevacizumab, erlotinib, lenvatinib mesylate capsules, regorafenib, lenvatinib, entecavir, extended polyethylene glycol, interferon, lamivudine, acoladine, Huachansu capsules, Kanglaite injection, Cidan capsules, sodium cantharidate vitamin B6 injection, Jinlong capsules, Biejiajian pills, Huaier granules, elemene injection, Kangai injection, Aidi injection, Ganfule capsules, Brucea javanica oil soft capsules, compound cantharidin capsules, transfer factors, immune checkpoint drugs, immunoglobulin G, Chaihu Shugan Powder, Gexia Zhuyu Decoction, Xiaoyao Powder, Yinchenhao Decoction combined with Wuling Powder, and Yiguanjian.
10. The drug according to claim 8 or 9, characterized in that The dosage form is a dosage form for enteral administration and / or a dosage form for parenteral administration; The dosage form for administration via the gastrointestinal tract is powder, tablet, granule, capsule, solution, emulsion or suspension; The non-intestinal administration dosage form is an injection dosage form, a respiratory tract administration dosage form, a skin administration dosage form, a mucosal administration dosage form or a cavity administration dosage form.
Citation Information
Patent Citations
Combined drug of gossypol acetate and chemotherapeutic drug
CN109876145A
Antitumor drug combined composition and application thereof
CN111420060A
Medicine composition applied to chemotherapy of tumors
CN113082210A
Methods for predicting cancer patient's clinical response to Anti-cancer compounds
US20180306800A1
Compounds, compositions and use for anticancer therapy
WO2010099731A1
